12 results
424B4
CGTX
Cognition Therapeutics Inc
14 Nov 22
Prospectus supplement with pricing info
6:02am
is presented on the right. Aβ oligomers shown in red bind to synaptic receptors and reduce numbers of synapses shown in green. The addition of CT1812 … administration of CT1812, the AD mice, represented by the solid green bars, were seen to perform at a level similar to that achieved by normal mice. We believe
DRS
CGTX
Cognition Therapeutics Inc
20 Oct 22
Draft registration statement
12:00am
to synaptic receptors and reduce numbers of synapses shown in green. The addition of CT1812 displaces Aβ oligomer binding and appears to block the effects … compared to normal, non-transgenic mice, represented by the blue bars. However, after administration of CT1812, the AD mice, represented by the solid green
10-K
2021 FY
CGTX
Cognition Therapeutics Inc
30 Mar 22
Annual report
7:40am
is presented on the right. Aβ oligomers shown in red bind to synaptic receptors and reduce numbers of synapses shown in green. The addition of CT1812 displaces … , after administration of CT1812, the AD mice, represented by the solid green bars, were seen to perform at a level similar to that achieved by normal
424B4
a2lhpe79scs0vk
12 Oct 21
Prospectus supplement with pricing info
4:11pm
S-1
s50vg1xl3p0e nd
19 Jul 21
IPO registration
7:02am
DRS/A
jhwig
23 Jun 21
Draft registration statement (amended)
12:00am
DRS
4dm8vzd9t7 tm0z3opg
7 May 21
Draft registration statement
12:00am
- Prev
- 1
- Next